Literature DB >> 8307140

Serological comparison of purified antigens 60 and 85A (P32) of Mycobacterium bovis BCG, and purified protein derivative, in active pulmonary tuberculosis.

M Turneer1, E Van Nerom.   

Abstract

The immunoglobulin G (IgG) response directed against Mycobacterium bovis BCG antigens 60 (A60) and 85A (P32), and purified protein derivative (PPD), was investigated in order to compare the serodiagnostic potentials of these antigens in tuberculosis (TB). The sera of 59 patients with active minimal or moderately advanced pulmonary TB and of 59 healthy control subjects were tested by enzyme-linked immunosorbent assay. The frequencies of positivity were significantly higher (P < 0.001) in patients than in controls and similar with all three antigens. The strongest correlation was found between the responses to A60 and PPD (P < 0.001), the weakest between the responses to A60 and P32 (P < 0.05). Discrepancies were observed in newly diagnosed patients before the institution of specific chemotherapy and in patients with negative direct smears at the time of diagnosis. Untreated patients with negative direct smears presented the lowest sensitivities. P32 was the most effective antigen in diagnosing these cases (50% positivity); A60 was not better than PPD (29% and 21% positivity, respectively). The results presented here emphasize the importance of comparing antigens with the same samples in order to allow their real respective evaluation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8307140     DOI: 10.1007/BF00209533

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  17 in total

1.  Preparation of purified tuberculin RT 23.

Authors:  M MAGNUSSON; M W BENTZON
Journal:  Bull World Health Organ       Date:  1958       Impact factor: 9.408

2.  Quantitative and qualitative studies on the major extracellular antigen of Mycobacterium tuberculosis H37Rv and Mycobacterium bovis BCG.

Authors:  H G Wiker; M Harboe; S Nagai; J Bennedsen
Journal:  Am Rev Respir Dis       Date:  1990-04

Review 3.  The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme-linked immunosorbent assay.

Authors:  T M Daniel; S M Debanne
Journal:  Am Rev Respir Dis       Date:  1987-05

4.  Evaluation of a dual-antigen ELISA test for the serodiagnosis of tuberculosis.

Authors:  S F Raheman; S Wagner; H Mauch; N D Vasudeva; D L Ingole
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

5.  Serodiagnosis of tuberculosis using an ELISA with antigen 5 and a hemagglutination assay with glycolipid antigens. Results in patients with newly diagnosed pulmonary tuberculosis ranging in extent of disease from minimal to extensive.

Authors:  S L Chan; Z Reggiardo; T M Daniel; D J Girling; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1990-08

6.  Humoral immune response in human tuberculosis: immunoglobulins G, A, and M directed against the purified P32 protein antigen of Mycobacterium bovis bacillus Calmette-Guérin.

Authors:  M Turneer; J P Van Vooren; J De Bruyn; E Serruys; P Dierckx; J C Yernault
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

7.  Serological analysis of human tuberculosis by an ELISA with mycobacterial antigen 60.

Authors:  M C Baelden; B Vanderelst; M Dieng; J Prignot; C Cocito
Journal:  Scand J Infect Dis       Date:  1990

8.  Enzyme-linked immunosorbent assay (ELISA) for antibodies to purified protein derivative of tuberculin (PPD). IgM-, IgA- and IgG- anti-PPD antibodies in active pulmonary tuberculosis.

Authors:  M K Viljanen; J Eskola; E Tala
Journal:  Eur J Respir Dis       Date:  1982-05

9.  Antibodies to mycobacteria in human tuberculosis. I. Development of antibodies before and after antimicrobial therapy.

Authors:  M H Kaplan; M W Chase
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

10.  Mycobacterial antigen complex A60-specific T-cell repertoire during the course of pulmonary tuberculosis.

Authors:  S Carlucci; A Beschin; L Tuosto; F Ameglio; G M Gandolfo; C Cocito; F Fiorucci; C Saltini; E Piccolella
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.